Adamas Pharmaceuticals, Inc.
(NASDAQ : ADMS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. -1.16%49.580.0%$329.46m
VRXValeant Pharmaceuticals International, Inc. 0.82%28.3014.1%$166.52m
HZNPHorizon Therapeutics Plc 0.59%113.625.5%$129.09m
ICLRICON plc 0.55%278.102.8%$116.60m
CTLTCatalent, Inc. 1.69%132.602.0%$101.95m
JAZZJazz Pharmaceuticals Plc 1.70%142.742.1%$95.19m
PRGOPerrigo Co. Plc 1.80%45.586.9%$75.17m
UTHRUnited Therapeutics Corp. -0.15%184.0514.0%$64.19m
ARGXargenx SE 1.99%297.750.0%$53.45m
BHCBausch Health Cos., Inc. 0.82%28.300.0%$43.84m
AXSMAxsome Therapeutics, Inc. -1.81%40.381.8%$41.31m
GRVIGrove, Inc. 3.47%6.380.0%$38.15m
PCRXPacira Biosciences, Inc. -1.28%52.409.8%$32.08m
ENDPEndo International Plc 0.48%4.188.5%$31.80m
IRWDIronwood Pharmaceuticals, Inc. -0.78%13.319.5%$24.02m

Company Profile

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.